Phaseline

Companies › Bellicum Pharmaceuticals

Bellicum Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 7 registered trials: 7 Phase 1; Oncology; next expected readout Oct 2032.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BPX-501 T cells (rivogenlecleucel)
T cells transduced with CaspaCIDe safety switch (inducible caspase-9)
CASP9Phase 1Acute Lymphoblastic Leukemia; Leukemia; Hematologic MalignancyOct 2032
rimiducid (AP1903)
Dimerizer drug that activates iCasp9 suicide switch to eliminate BPX-501 cells in case of
–Phase 1Acute Lymphoblastic Leukemia; Leukemia; Hematologic MalignancyOct 2032

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT01744223BPX-501 T cells (rivogenlecleucel)Phase 1Acute Lymphoblastic LeukemiaOncologyOct 2032
NCT01744223rimiducid (AP1903)Phase 1Acute Lymphoblastic LeukemiaOncologyOct 2032
NCT02477878BPX-501 T cells (rivogenlecleucel)Phase 1LeukemiaOncologyJan 2033
NCT02477878rimiducid (AP1903)Phase 1LeukemiaOncologyJan 2033
NCT03301168BPX-501 T cells (rivogenlecleucel)Phase 1Acute Lymphoblastic LeukemiaOncologyMay 2034
NCT03459170BPX-501 T cells (rivogenlecleucel)Phase 1Hematologic MalignancyOncologySep 2035
NCT03459170rimiducid (AP1903)Phase 1Hematologic MalignancyOncologySep 2035

Targets

CASP9 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.